Pharma and Biotech
Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | n/a | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | n/a | n/a |
Pr/Book | 1.1 |
Latest | F'cast | |
---|---|---|
Revenue | n/a | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | 0.52 | (0.45) | (0.65)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 0.22 | (0.95) | (1.36)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 0.54 | (2.70) | (2.61)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-23 | 0.59 | (3.12) | (3.00)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-24 | n/a | (1.45) | (0.12)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Proposed acquisition of Awakn approved | 23-Apr-2025 | 07:00 | RNS |
Final Results for the year ended 31 December 2024 | 16-Apr-2025 | 07:00 | RNS |
Posting of Circular and Notice of General Meeting | 10-Apr-2025 | 14:00 | RNS |
Graft Polymer to buy Awakn in £4.98m deal | 16-Dec-2024 | ShareCast |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 0.15p |
Change Today | 0.008p |
% Change | 5.17 % |
52 Week High | 1.01 |
52 Week Low | 0.12 |
Volume | 9,608,088 |
Shares Issued | 2,295.93m |
Market Cap | £3.50m |
Beta | 0.02 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth | ![]() |
---|
No dividends found |
Time | Volume / Share Price |
11:07 | 1,135,995 @ 0.15p |
10:51 | 154,142 @ 0.15p |
09:04 | 186,487 @ 0.16p |
09:02 | 7,000 @ 0.15p |
09:02 | 1,400 @ 0.15p |
CEO | Anthony Tennyson |
Chair | Dennis Purcell |
Finance Director | Ryan Neats |
You are here: research